Profile of antiretroviral agents use in Colombia

Jorge E. Machado-Alba, Miguel A. Atehortua-Otero, Diego A. Cortés-Mejía, .

Keywords: Acquired immunodeficiency syndrome, antiretroviral therapy, highly active, drug prescriptions, pharmacoepidemiology

Abstract

Introduction: Since the beginning of the epidemic, human immunodeficiency virus (HIV) has taken more than 36 million lives.
Objective: To determine the antiretroviral drug prescription patterns in a population of individuals with HIV infection in Colombia.
Materials and methods: Cross-sectional study analyzing the profiles of patients treated with antiretroviral drugs between April 1st and September 30th, 2015. The sociodemographic, pharmacological, and comorbidity variables were identified. Individuals with a positive diagnosis of HIV of all ages and both genders were included.
Results: We found 641 patients with a mean age of 39.0±17 years who were predominantly male (60.2%). The most used medications were lamivudine-zidovudine (51.6%), lopinavir-ritonavir (36%) and efavirenz (24.5%). The combination of lamivudine-zidovudine plus lopinavir-ritonavir was the most prescribed regimen (29.5%), but a total of 80 different regimens was identified. Being an adult between the ages of 45-64 years (OR=2.25; 95%CI 1.367-3.713) was associated with a greater probability
of receiving 4 or more antiretrovirals. A total of 267 (41.6%) patients used at least one comedication (range: 1-18 drugs), especially anti-ulcer (57.3%), lipid-lowering (28.8%) and anti-hypertensive (28.5%) drugs.
Conclusions: Patients undergoing antiretroviral treatment are receiving medications with elevated intrinsic values at the recommended doses and present comorbidities associated with chronic agerelated conditions. However, these patients receive a great variety of regimens that are not included in the clinical practice guidelines.

Downloads

Download data is not yet available.
  • Jorge E. Machado-Alba Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira, Audifarma, S. A., Pereira, Colombia
  • Miguel A. Atehortua-Otero Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira, Audifarma, S. A., Pereira, Colombia
  • Diego A. Cortés-Mejía Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira, Audifarma, S. A., Pereira, Colombia

References

Kharsany AB, Karim QA. HIV Infection and AIDS in Sub-Saharan Africa: Current status, challenges and opportunities. Open AIDS J. 2016;10:34-48. https://doi.org/10.2174/1874613601610010034

Friedland G. Marking time in the Global HIV/AIDS pandemic. JAMA. 2016;316:145-6. https://doi.org/10.1001/jama.2016.9006

Fettig J, Swaminathan M, Murrill CS, Kaplan JE. Global epidemiology of HIV. Infect Dis Clin North Am. 2014;28:323-37. https://doi.org/10.1016/j.idc.2014.05.001

Sabin CA, Lundgren JD. The natural history of HIV infection. Curr Opin HIV AIDS. 2013;8:311-7. https://doi. org/10.1097/COH.0b013e328361fa66

Hammer SM. Clinical practice. Management of newly diagnosed HIV infection. N Engl J Med. 2005;353:1702-10. https://doi.org/10.1056/NEJMcp051203

Esté JA, Cihlar T. Current status and challenges of antiretroviral research and therapy. Antiviral Res. 2010;85:25-33. https://doi.org/10.1016/j.antiviral.2009.10.007

Pau AK, George JM. Antiretroviral therapy: Current drugs. Infect Dis Clin North Am. 2014;28:371-402. https://doi.org/10.1016/j.idc.2014.06.001

Sawyer JR, Ma Q, Hsiao CB. Single-tablet, once-daily treatment regimens for HIV. Lancet Infect Dis. 2014;14:265-7. https://doi.org/10.1016/S1473-3099(14)70026-X

Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376:49-62. https://doi.org/10.1016/S0140-6736(10)60676-9

Maartens G, Celum C, Lewin SR. HIV infection: Epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014;384:258-71. https://doi.org/10.1016/S0140-6736(14)60164-1

Machado JE, Alzate JA. Patrones de prescripción de antirretrovirales en 997 pacientes colombianos. Biomédica. 2008;28:78-86. https://doi.org/10.7705/biomedica. v28i1.110

Machado-Alba JE, Vidal X. Effectiveness of antiretroviral treatment in Colombia. Rev Panam Salud Pública. 2012;32:360-7.

Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, et al. International Antiviral Society-USA Panel. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312:410-25. https://doi.org/10.1001/jama.2014.8722

Johnson JA, Sax PE. Beginning antiretroviral therapy for patients with HIV. Infect Dis Clin North Am. 2014;28:421-38. https://doi.org/10.1016/j.idc.2014.06.003

Crawford KW, Ripin DH, Levin AD, Campbell JR, Flexner C, participants of Conference on Antiretroviral Drug Optimization. Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: A consensus statement. Lancet Infect Dis. 2012;12:550-60. https://doi.org/10.1016/S1473-3099(12)70134-2

Werneck-Silva AL, Prado IB. Dyspepsia in HIV-infected patients under highly active antiretroviral therapy. J Gastroenterol Hepatol. 2007;22:1712-6. https://doi.org/10. 1111/j.1440-1746.2007.04897.x

Dagenais-Lussier X, Mouna A, Routy JP, Tremblay C, Sekaly RP, El-Far M, et al. Current topics in HIV-1 pathogenesis: The emergence of deregulated immunometabolism

in HIV-infected subjects. Cytokine Growth Factor Rev. 2015;26:603-13. https://doi.org/10.1016/j.cytogfr.2015.09.001

Amariles P, Giraldo NA, Faus MJ. Interacciones medicamentosas en pacientes infectados con el VIH: aproximación para establecer y evaluar su relevancia clínica. Farm Hosp. 2007;31:283-302.

Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007;167:684-91. https://doi.org/10.1001/archinte.167.7.684

Martin CP, Fain MJ, Klotz SA. The older HIV-positive adult: A critical review of the medical literature. Am J Med. 2008;121:1032-7. https://doi.org/10.1016/j.amjmed.2008.08.009

Luther VP, Wilkin AM. HIV infection in older adults. Clin Geriatr Med. 2007;23:567-83. https://doi.org/10.1016/j.cger.2007.02.004

Cardoso SW, Torres TS, Santini-Oliveira M, Marins LMS, Veloso VG, Grinsztejn B. Aging with HIV: A practical review. Braz J Infect Dis. 2013;17:464-79. https://doi.org/10.1016/j.bjid.2012.11.007

Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamics and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013;52:981-94. https://doi.org/10.1007/s40262-013-0093-2

How to Cite
1.
Machado-Alba JE, Atehortua-Otero MA, Cortés-Mejía DA. Profile of antiretroviral agents use in Colombia. biomedica [Internet]. 2018 Dec. 1 [cited 2024 May 17];38(4):527-33. Available from: https://revistabiomedica.org/index.php/biomedica/article/view/3885

Some similar items:

Published
2018-12-01
Section
Original articles

Altmetric

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
Crossref Cited-by logo
QR Code